Your browser doesn't support javascript.
loading
Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study.
Bruschi, Maurizio; Moroni, Gabriella; Sinico, Renato Alberto; Franceschini, Franco; Fredi, Micaela; Vaglio, Augusto; Cavagna, Lorenzo; Petretto, Andrea; Pratesi, Federico; Migliorini, Paola; Locatelli, Francesco; Pazzola, Giulia; Pesce, Giampaola; Bagnasco, Marcello; Manfredi, Angelo; Ramirez, Giuseppe A; Esposito, Pasquale; Murdaca, Giuseppe; Negrini, Simone; Cipriani, Leda; Trezzi, Barbara; Emmi, Giacomo; Cavazzana, Ilaria; Binda, Valentina; d'Alessandro, Matteo; Fenaroli, Paride; Pisani, Isabella; Garibotto, Giacomo; Montecucco, Carlomaurizio; Santoro, Domenico; Scolari, Francesco; Volpi, Stefano; Mosca, Marta; Tincani, Angela; Candiano, Giovanni; Prunotto, Marco; Verrina, Enrico; Angeletti, Andrea; Ravelli, Angelo; Ghiggeri, Gian Marco.
Affiliation
  • Bruschi M; Laboratory of Molecular Nephrology, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Moroni G; Division of Nephrology and Dialysis, Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milano, Italy.
  • Sinico RA; Department of Medicine and Surgery, University of Milan, Bicocca, Italy.
  • Franceschini F; Rheumatology and Clinical Immunology, ASST SpedaliCivili and Università of Brescia, Brescia, Italy.
  • Fredi M; Rheumatology and Clinical Immunology, ASST SpedaliCivili and Università of Brescia, Brescia, Italy.
  • Vaglio A; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Firenze, Firenze, Italy.
  • Cavagna L; Nephrology and Dialysis Unit, Meyer Children's Hospital, Firenze, Italy.
  • Petretto A; Division of Rheumatology, University and IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Pratesi F; Core Facilities-Proteomics Laboratory, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Migliorini P; Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Italy.
  • Locatelli F; Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Italy.
  • Pazzola G; Division of Rheumatology, University and IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Pesce G; Nephrology and Dialysis, Arciospedale Santa Maria Nuova, Reggio Emilia, Italy.
  • Bagnasco M; Medical and Radiometabolic Therapy Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Manfredi A; Medical and Radiometabolic Therapy Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Ramirez GA; Unit of Internal Medicine and Immunology, IRCCS Ospedale San Raffaele, Milano, Italy.
  • Esposito P; Unit of Internal Medicine and Immunology, IRCCS Ospedale San Raffaele, Milano, Italy.
  • Murdaca G; Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Negrini S; Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Cipriani L; Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Trezzi B; Division of Nephrology, University of Genoa and Policlinico San Martino, Genova, Italy.
  • Emmi G; Department of Medicine and Surgery, University of Milan, Bicocca, Italy.
  • Cavazzana I; Lupus Clinic Department of Biomedicine, University of Florence, University Hospital Careggi, Florence, Italy.
  • Binda V; Rheumatology and Clinical Immunology, ASST SpedaliCivili and Università of Brescia, Brescia, Italy.
  • d'Alessandro M; Division of Nephrology and Dialysis, Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milano, Italy.
  • Fenaroli P; Division of Nephrology, Dialysis and Transplantation, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Pisani I; Nephrology Unit, University Hospital, University of Parma, Parma, Italy.
  • Garibotto G; Nephrology Unit, University Hospital, University of Parma, Parma, Italy.
  • Montecucco C; Division of Nephrology, University of Genoa and Policlinico San Martino, Genova, Italy.
  • Santoro D; Division of Rheumatology, University and IRCCS Policlinico S. Matteo, Pavia, Italy.
  • Scolari F; Nephrology and Dialysis Unit, University of Messina and G Martino Hospital, Messina, Italy.
  • Volpi S; Division of Nephrology and Dialysis, University of Brescia and Ospedale di Montichiari, Brescia, Italy.
  • Mosca M; Division of Paediatric Rheumatology Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Tincani A; Rheumatologu Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Candiano G; Rheumatology and Clinical Immunology, ASST SpedaliCivili and Università of Brescia, Brescia, Italy.
  • Prunotto M; Laboratory of Molecular Nephrology, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Verrina E; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
  • Angeletti A; Division of Nephrology, Dialysis and Transplantation, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Ravelli A; Division of Nephrology, Dialysis and Transplantation, Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Ghiggeri GM; Division of Paediatric Rheumatology Scientific Institute for Research and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Rheumatology (Oxford) ; 60(7): 3388-3397, 2021 07 01.
Article in En | MEDLINE | ID: mdl-33351137
OBJECTIVES: Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. METHODS: Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n=91) and SLE (n=31) and in other patients with SLE recruited within 2 years from diagnosis (n=99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. RESULTS: LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T0 and presented the maximal decrement within 12 months. CONCLUSIONS: Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. TRIAL REGISTRATION: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Immunoglobulin G / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2021 Type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Immunoglobulin G / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2021 Type: Article Affiliation country: Italy